«We showed that there are markers on these stomach
tumour cells that indicate they would be responsive to a
type of immunotherapy called immune checkpoint inhibitors, in
particular anti-PDL1 immunotherapy, which is already used with great success in the treatment of melanoma and certain other cancers.